Country operational research priorities pending.
Is there still LF transmission after successful TAS 3?
This study builds on the methods developed for the operational studies ongoing in Ghana and Burkina Faso. The first two research questions are the same as those earlier studies with two new questions added here- question 3 on triple drug therapy (ivermectin, DEC, albendazole – IDA) and 4 on the use of a new rapid ethnography approach.
- What factors are associated with effective (and lower) MDA coverage as defined as availability, accessibility, and acceptability in settings that have repeatedly failed Pre-TAS?
- What is the impact of an adapted and tailored intervention package on achieving effective coverage?
- What messages and community engagement approaches are needed to ensure the acceptability of IDA triple drug therapy in Nepal?
- How does the rapid ethnography approach compare to more traditional qualitative analysis methods in terms of cost, timeliness, and ability to provide required information for programmatic decisions? Can local capacity for use of this approach be built rapidly?